Literature DB >> 12960055

Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

Jan A Ehses1, Vanbric R Casilla, Tim Doty, J Andrew Pospisilik, Kyle D Winter, Hans-Ulrich Demuth, Raymond A Pederson, Christopher H S McIntosh.   

Abstract

The incretin glucose-dependent insulinotropic polypeptide (GIP) is a major regulator of postprandial insulin secretion in mammals. Recent studies in our laboratory, and others have suggested that GIP is a potent stimulus for protein kinase activation, including the MAPK (ERK1/2) module. Based on these studies, we hypothesized that GIP could regulate cell fate and sought to examine the underlying mechanisms involved in GIP stimulation of cell survival. GIP potentiated glucose-induced beta-(INS-1)-cell growth to levels comparable with GH and GLP-1 while promoting cell survival in the face of serum and glucose-deprivation or treatment with wortmannin or streptozotocin. In the absence of GIP, 50% of cells died after 48 h of serum and glucose withdrawal, whereas 91 +/- 10% of cells remained viable in the presence of GIP [n = 3, P < 0.05; EC50 of 1.24 +/- 0.48 nm GIP (n = 4)]. Effects of GIP on cell survival and inhibition of caspase-3 were mimicked by forskolin, but pharmacological experiments excluded roles for MAPK kinase (Mek)1/2, phosphatidylinositol 3-kinase, protein kinase A, Epac, and Rap 1. Survival effects of GIP were ablated by the inhibitor SB202190, indicating a role for p38 MAPK. Furthermore, caspase-3 activity was also regulated by p38 MAPK, with a lesser role for Mek1/2, based on RNA interference studies. We propose that GIP is able to reverse caspase-3 activation via inhibition of long-term p38 MAPK phosphorylation in response to glucose deprivation (+/-wortmannin). Intriguingly, these findings contrasted with short-term phosphorylation of MKK3/6-->p38 MAPK-->ATF-2 by GIP. Thus, these data suggest that GIP is able to regulate INS-1 cell survival by dynamic control of p38 MAPK phosphorylation via cAMP signaling and lend further support to the notion that GIP regulation of MAPK signaling is critical for its regulation of cell fate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960055     DOI: 10.1210/en.2002-0068

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  41 in total

1.  Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

Authors:  Y Takeda; Y Fujita; J Honjo; T Yanagimachi; H Sakagami; Y Takiyama; Y Makino; A Abiko; T J Kieffer; M Haneda
Journal:  Diabetologia       Date:  2011-11-10       Impact factor: 10.122

2.  Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase.

Authors:  Sameer Mohammad; Lavoisier S Ramos; Jochen Buck; Lonny R Levin; Francesco Rubino; Timothy E McGraw
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

4.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

5.  Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide.

Authors:  Scott B Widenmaier; Arthur V Sampaio; T Michael Underhill; Christopher H S McIntosh
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function.

Authors:  Simone Renner; Christiane Fehlings; Nadja Herbach; Andreas Hofmann; Dagmar C von Waldthausen; Barbara Kessler; Karin Ulrichs; Irina Chodnevskaja; Vasiliy Moskalenko; Werner Amselgruber; Burkhard Göke; Alexander Pfeifer; Rüdiger Wanke; Eckhard Wolf
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

8.  A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control.

Authors:  Scott B Widenmaier; Su-Jin Kim; Gary K Yang; Thomas De Los Reyes; Cuilan Nian; Ali Asadi; Yutaka Seino; Timothy J Kieffer; Yin Nam Kwok; Christopher H S McIntosh
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

9.  Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  Diabetes       Date:  2010-04-05       Impact factor: 9.461

10.  Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

Authors:  Su-Jin Kim; Cuilan Nian; Doris J Doudet; Christopher H S McIntosh
Journal:  Diabetes       Date:  2008-12-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.